Hims & Hers shares surged 14% after Robert F Kennedy Jr signaled the FDA may allow roughly 14 peptides back into US compounding. He argued previous restrictions fueled a black market. Analysts identify Hims as a major potential beneficiary of broader peptide access, though the company currently counts few GLP-1 users.